A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema. [electronic resource]
Producer: 20160811Description: 841-9 p. digitalISSN:- 1549-4713
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- administration & dosage
- Bevacizumab -- administration & dosage
- Cross-Over Studies
- Diabetes Mellitus, Type 1 -- complications
- Diabetes Mellitus, Type 2 -- complications
- Diabetic Retinopathy -- drug therapy
- Double-Blind Method
- Female
- Humans
- Intravitreal Injections
- Macular Edema -- drug therapy
- Male
- Middle Aged
- Ranibizumab -- administration & dosage
- Research Design
- Retina -- pathology
- Tomography, Optical Coherence
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
- Visual Acuity -- drug effects
No physical items for this record
Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.